Dicerna Pharmaceuticals, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
In the following press release, the company announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for DCR-PH1.
“Dicerna is developing DCR-PH1, which is in preclinical development, for the treatment of PH1. In preclinical studies, DCR-PH1 induced inhibition of HAO1 and significantly reduced levels of urinary oxalate in animal models of PH1. ” Read the full article.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James C. Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA. [Source: MarketWatch]
Company Website: http://dicerna.com